Lilly’s oral GLP‑1 faces scrutiny

Eli Lilly’s new obesity pill reached the U.S. market on April 1, but the Food and Drug Administration is already demanding years of extra safety follow-up. (fda.gov) The drug, sold as Foundayo and known chemically as orforglipron, was approved for adults with obesity or overweight plus a weight-related condition after a 50-day review under the Food and Drug Administration’s National Priority Voucher pilot. The agency said that was 294 days ahead of the application’s original January 20, 2027 target date. (fda.gov) Foundayo is a glucagon-like peptide-1, or GLP-1, receptor agonist in tablet form, taken once a day by mouth. Eli Lilly said patients on the highest dose in its ATTAIN-1 trial lost an average 27.3 pounds, or 12.4%, among those who stayed on treatment. (lilly.com) A GLP-1 drug mimics a gut hormone that helps people feel full and slows stomach emptying, which is why pills that work this way are seen as easier-to-use alternatives to weekly injections. Foundayo can be taken without food or water restrictions, a point Lilly has emphasized in its launch. (fda.gov) (lilly.com) The Food and Drug Administration’s approval letter did not reopen the approval itself, but it said the data available at approval were not enough to fully characterize several risks. Pharmaceutical Executive, citing the letter and Lilly’s update, reported the agency asked for added tracking of cardiovascular events, drug-induced liver injury, and delayed gastric emptying. (pharmexec.com) (accessdata.fda.gov) That request runs well past a typical launch cycle. Pharmaceutical Executive reported the Food and Drug Administration required at least 15 years of thyroid-cancer follow-up, plus a pediatric obesity registry and a pregnancy exposure registry to capture outcomes not fully covered in pre-approval trials. (pharmexec.com) The label already carries a boxed warning about thyroid C-cell tumors, the same class of warning seen on other obesity drugs in this category. Lilly’s prescribing information says orforglipron did not produce tumors in rodents because it was not pharmacologically active in rats or mice, but the human relevance of GLP-1-related thyroid tumors remains undetermined. (pi.lilly.com) Lilly has argued the broader safety picture remains intact. Pharmaceutical Executive said the company released updated data showing non-inferior cardiovascular safety versus insulin glargine in ACHIEVE-4, with a 16% lower observed rate of major adverse cardiovascular events and an exploratory 57% lower all-cause mortality. (pharmexec.com) The launch is also colliding with an older problem in the weight-loss market: fake products moving through real channels. On December 5, 2025, the Food and Drug Administration said it had seized dozens of counterfeit Ozempic units that had entered the legitimate U.S. drug supply chain outside Novo Nordisk’s authorized distribution network. (fda.gov) The agency said those counterfeit pens used an authentic lot number, PAR1229, and told pharmacies, wholesalers, and patients to inspect packaging details before dispensing or using the drug. For Lilly, the result is a launch in which convenience and scale are central selling points, while regulators are demanding longer proof that the pill stays safe in the real world. (fda.gov) (lilly.com)